ArticleScientific reports2026
Vitamin C protects oligodendrocyte lineage cells and modulates microglial inflammation during OGD/R in vitro.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To investigate the protective effects of vitamin C (VitC) against oxygen-glucose deprivation/reoxygenation (OGD/R) injury and its underlying mechanisms involving oxidative stress and inflammation in oligodendrocyte lineage cells and microglia. Primary rat oligodendrocyte precursor cells (OPCs), mature oligodendrocytes (OLs), and BV2 microglia were subjected to OGD/R with or without VitC. Apoptosis (TUNEL), differentiation (MBP⁺/PDGFRα⁺), oxidative stress (ROS, MDA), and microglial cytokine profiles (qRT-PCR/ELISA) were assessed. Co-culture experiments were conducted in transwell systems using primary rat OPCs or mature OLs seeded in the upper inserts and BV2 microglia seeded in the lower chambers, allowing paracrine communication without direct cell-cell contact. Biological replicates: n = 3-5 litters for primary cells; ≥3 passages for BV2. OGD/R increased apoptosis in OPCs(P < 0.01) and OLs(P < 0.01) and impaired OPC differentiation(P < 0.001); VitC attenuated apoptosis (OPCs: P < 0.01; OLs: P < 0.05) and restored differentiation(P < 0.01). VitC reduced OGD/R‑induced elevations in intracellular ROS and MDA (all P < 0.05). In BV2 microglia, VitC suppressed pro-inflammatory (COX-2, IL-1β, IL-6, TNF-α, iNOS) and enhanced anti-inflammatory (IL-10, CD206) markers at both mRNA and protein levels (all P < 0.05). In co-culture, OGD/R increased OPCs apoptosis (P < 0.001) and reduced differentiation (both vs. CON, P < 0.001), with VitC normalizing these parameters (P < 0.01). Cytokine changes mirrored those in monocultures. Notably, OGD/R did not alter OLs apoptosis in OL-BV2 co-cultures (P > 0.05). VitC (5 µg/mL) protects oligodendrocyte lineage cells via direct antioxidant effects and bidirectional modulation of microglial inflammation, supporting its potential as a multi‑target agent for white‑matter disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.